SalvaRx doubles as it sells immuno-oncology assets to Portage for US$76mln

05:49 EDT 14 Aug 2018 | Proactive Investors

Junior drug developer SalvaRx is to become an AIM Rule 15 cash shell after selling off its portfolio of immuno-oncology assets to Portage for US$75mln in an all-share deal

More From BioPortfolio on "SalvaRx doubles as it sells immuno-oncology assets to Portage for US$76mln"